Trials / Completed
CompletedNCT03931681
A Study of OKI-179 in Patients With Solid Tumors
A Phase 1 Study of OKI-179 as a Single Agent in Patients With Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 34 (actual)
- Sponsor
- OnKure, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is a Phase 1, single center, open-label study, assessing single agent dose escalation of OKI-179.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | OKI-179 | OKI-179 single agent |
Timeline
- Start date
- 2019-05-08
- Primary completion
- 2021-11-27
- Completion
- 2021-11-27
- First posted
- 2019-04-30
- Last updated
- 2021-12-06
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03931681. Inclusion in this directory is not an endorsement.